Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells $514,262.80 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Eben Tessari sold 12,470 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $41.24, for a total value of $514,262.80. Following the sale, the chief operating officer directly owned 22,714 shares of the company’s stock, valued at $936,725.36. This trade represents a 35.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Eben Tessari also recently made the following trade(s):

• On Tuesday, October 14th, Eben Tessari sold 12,368 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $37.67, for a total transaction of $465,902.56.
• On Monday, September 29th, Eben Tessari sold 42,000 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $38.33, for a total transaction of $1,609,860.00.
• On Monday, September 15th, Eben Tessari sold 16,400 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $36.46, for a total transaction of $597,944.00.
• On Thursday, September 4th, Eben Tessari sold 85,271 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $35.52, for a total transaction of $3,028,825.92.
• On Friday, September 5th, Eben Tessari sold 13,389 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $35.66, for a total transaction of $477,451.74.
• On Wednesday, September 3rd, Eben Tessari sold 15,091 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $35.50, for a total value of $535,730.50.

Kiniksa Pharmaceuticals International Trading Up 2.1%

Shares of NASDAQ KNSA traded up $0.88 during trading on Wednesday, reaching $42.16. 361,832 shares of the company traded hands, compared to its average volume of 618,670. The stock has a market cap of $3.20 billion, a P/E ratio of 93.69 and a beta of 0.16. The firm’s fifty day simple moving average is $38.13 and its 200 day simple moving average is $32.63. Kiniksa Pharmaceuticals International, plc has a 12-month low of $17.82 and a 12-month high of $42.30.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The firm had revenue of $180.86 million for the quarter, compared to analyst estimates of $166.64 million. During the same period in the previous year, the business earned ($0.18) EPS. Kiniksa Pharmaceuticals International’s revenue for the quarter was up 61.2% compared to the same quarter last year. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, research analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on KNSA. Wells Fargo & Company upped their price target on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an “overweight” rating in a report on Thursday, September 25th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, October 8th. Jefferies Financial Group increased their target price on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a “buy” rating in a research report on Tuesday, July 29th. TD Cowen began coverage on shares of Kiniksa Pharmaceuticals International in a research note on Monday, September 29th. They issued a “buy” rating and a $60.00 price target on the stock. Finally, Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $52.00.

Institutional Trading of Kiniksa Pharmaceuticals International

Several large investors have recently made changes to their positions in KNSA. Nuveen LLC acquired a new position in Kiniksa Pharmaceuticals International in the 1st quarter valued at $16,992,000. Arrowstreet Capital Limited Partnership acquired a new stake in Kiniksa Pharmaceuticals International during the 2nd quarter worth $20,349,000. Qube Research & Technologies Ltd grew its holdings in shares of Kiniksa Pharmaceuticals International by 277.8% during the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after buying an additional 653,236 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 170.3% during the first quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company’s stock worth $22,961,000 after buying an additional 651,700 shares in the last quarter. Finally, Rubric Capital Management LP raised its position in shares of Kiniksa Pharmaceuticals International by 15.6% in the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock valued at $108,184,000 after buying an additional 526,567 shares during the last quarter. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.